{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Brownlee S"],"funding":["Octapharma"],"pagination":["342-348"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9680362"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(4)"],"pubmed_abstract":["<h4>Objective</h4>Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig<sup>®</sup> treatment offered a tolerable and safe alternative treatment for immunodeficient patients.<h4>Methods</h4>A one-year prospective cohort study was conducted at a single center in Ottawa, Canada. Adult immunodeficient patients who reported previous intolerability, adverse events, or other difficulty to other 20% SCIG product(s) were recruited to start on 16.5% Cutaquig<sup>®</sup>. Treatment tolerability, safety, and quality of life were observed and described.<h4>Results</h4>Seven out of ten patients tolerated Cutaquig<sup>®</sup>. There were no serious or severe adverse events "],"journal":["Hematology reports"],"pubmed_title":["Cutaquig<sup>®</sup> Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products."],"pmcid":["PMC9680362"],"funding_grant_id":["NA"],"pubmed_authors":["Cowan J","Kana'an MF","Cameron DW","Allen C","Brownlee S"],"additional_accession":[]},"is_claimable":false,"name":"Cutaquig<sup>®</sup> Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products.","description":"<h4>Objective</h4>Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig<sup>®</sup> treatment offered a tolerable and safe alternative treatment for immunodeficient patients.<h4>Methods</h4>A one-year prospective cohort study was conducted at a single center in Ottawa, Canada. Adult immunodeficient patients who reported previous intolerability, adverse events, or other difficulty to other 20% SCIG product(s) were recruited to start on 16.5% Cutaquig<sup>®</sup>. Treatment tolerability, safety, and quality of life were observed and described.<h4>Results</h4>Seven out of ten patients tolerated Cutaquig<sup>®</sup>. There were no serious or severe adverse events ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T00:35:08.899Z","creation":"2025-02-19T04:37:30.316Z"},"accession":"S-EPMC9680362","cross_references":{"pubmed":["36412628"],"doi":["10.3390/hematolrep14040048"]}}